At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TRAW TRAWS PHARMA
Trading 04-13 13:38:01 EDT
1.59
+0.11
+7.28%
High1.59Low1.51Vol14.60K
Open1.55D1 Closing1.48Amplitude5.59%
Mkt Cap12.69MTradable Cap9.41MTotal Shares7.99M
T/O22.60KT/O Rate0.25%Tradable Shares5.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement
Reuters  ·  04-09
Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement
Traws Pharma delays annual report filing, seeks 15-day extension
Reuters  ·  04-01
Traws Pharma delays annual report filing, seeks 15-day extension
Traws Pharma Inc expected to post a loss of $1.22 a share - Earnings Preview
Reuters  ·  03-27
Traws Pharma Inc expected to post a loss of $1.22 a share - Earnings Preview
BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold
Reuters  ·  02-19
BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold
BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients
Reuters  ·  02-19
BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients
Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients
Reuters  ·  02-19
Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
THOMSON REUTERS  ·  02-19
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind
THOMSON REUTERS  ·  02-19
Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind
Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16
THOMSON REUTERS  ·  02-19
Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16
Traws Pharma initiated with a Buy at Ladenburg
TIPRANKS  ·  01-30
Traws Pharma initiated with a Buy at Ladenburg
Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study
Reuters  ·  01-26
Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
GlobeNewswire  ·  01-26
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma Files IND Application for Tivoxavir Marboxil Influenza Therapy
Reuters  ·  01-13
Traws Pharma Files IND Application for Tivoxavir Marboxil Influenza Therapy
Traws Pharma Inc: Full Study Enrollment Expected in January 2026
THOMSON REUTERS  ·  01-13
Traws Pharma Inc: Full Study Enrollment Expected in January 2026
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (Ind) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in Paxlovid®-Eligible and Ineligible Covid-19 Patients
THOMSON REUTERS  ·  01-13
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (Ind) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in Paxlovid®-Eligible and Ineligible Covid-19 Patients
Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients
Reuters  ·  2025-12-17
Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients
Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds
THOMSON REUTERS  ·  2025-12-17
Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds
Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026
THOMSON REUTERS  ·  2025-12-17
Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026
Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients
THOMSON REUTERS  ·  2025-12-17
Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients
Traws Pharma Grants Stock Options and RSUs to Executive Team
Reuters  ·  2025-12-17
Traws Pharma Grants Stock Options and RSUs to Executive Team

Introduction

Company Name.
TRAWS PHARMA
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--